Incidence of oral human papillomavirus infection

Source: The LancetPublished: November 9, 2013By: Zoe R. Edelstein, Stephen Schwartz, Laura A. Koutsky   Aimée Kreimer and colleagues (Sept 7, p 877)1 report an annual incidence of oral human papillomavirus (HPV) infection of 4·4% in an international cohort of men (aged 18—73 years; n=1626; specimen collection every 6 months). We would like to offer a methodological explanation for the difference between this estimate and our estimate of 12·3% from a cohort in Seattle, WA, USA (aged 18—24 years; n=212; specimen collection every 4 months).2 There are several potential explanations, including differences in study population, sample size, and specimen collection schedule. We suggest that one of the main reasons is the difference in specimen collection method. Kreimer and colleagues measured HPV DNA using an oral rinse and gargle, whereas we used both an oral rinse and gargle and a self-collected swab of the back of the throat. In our paper, we also reported an incidence of 6·3% of oral HPV infection on the basis of the rinse-and-gargle method alone, which is closer to the 4·4% reported by Kreimer and colleagues. Pickard and colleagues3 estimated oral HPV incidence of 5·7 per 1000 person-months using a rinse-and-gargle method in a cohort of male and female US college students followed up for 3 months—corresponding to a 6·8% annual incidence. The similarity between these incidence estimates suggests that, to date, there is little evidence that oral HPV infection risk varies greatly across studies that differ in the composition of their study populations. * This news [...]

2013-11-08T12:51:17-07:00November, 2013|Oral Cancer News|

Vaccines plus screening could end cervical cancer

Source: www.cancernetwork.com Author: Fram Lowry Out with the old and in with the new is a commonly followed maxim in medicine given the rapid pace of developments in diagnosis and treatment. Human papillomavirus vaccines are relative newcomers to the cervical cancer armamentarium, but they cannot be relied on to do the job on their own; screening is still a must. Richard B. Roden, PhD, from Johns Hopkins University in Baltimore, and Carlos L. Santos, MD, from the Instituto Nacional de Enfermedades Neoplasicas in Lima, Peru, discussed the merits and drawbacks of HPV vaccines and standard screening during a session on female malignancies at ASCO 2009 in Orlando Long-term protection The widespread vaccination of adolescents against HPV will be critical to the eradication of cervical cancer, said Dr. Roden, an associate professor in the department of pathology. “HPV virus-like particle [VLP] vaccines are very effective in preventing genital HPV infection and neoplastic disease,” he explained. “Solid protection has been observed for more than six years after vaccination, suggesting vaccine protection is likely to be long-term, although the need for a booster is not out of the question.” To date, two HPV vaccines are FDA-approved: Gardasil from Merck, produced in yeast, and Cervarix from GlaxoSmithKline, produced in insect cells. In October 2009, Gardasil was approved by the FDA for use in boys and men (aged 9-26) for the prevention of genital warts caused by HPV-6 and HPV-11. Both vaccines target HPV-16 and HPV-18, the two most common oncogenic HPV types. Gardasil also [...]

2009-12-30T13:16:35-07:00December, 2009|Oral Cancer News|
Go to Top